New screening method for HPV-positive head and neck cancer
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
New findings about how long genes become less active with age could impact treatments for neurodegeneration, among other conditions.
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
Researchers have developed an algorithm which could improve diagnostics of ovarian high-grade serous carcinoma.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Researchers have discovered that higher expression of gigaxonin suppresses aggressive growth of human head and neck cancer cells.
Researchers have identified that AF1q is highly expressed in neuroblastoma, and could be used to destabilise N-Myc.
In this Q&A, esteemed Dr Rhoda Alani discusses the epigenetic landscape of therapy resistant melanomas and elucidates how corin treatment impacts the reprogramming of melanoma cell phenotypes. The findings suggest a new treatment paradigm for melanoma which could also be relevant to targeted therapy resistance mechanisms for other cancer types.